Oncology in the Time of COVID

The COVID-19 pandemic has been challenging for healthcare systems worldwide – with an already overburdened system and large population, the Indian healthcare system was no exception.

Ipsos white paper - Oncology in the Time of COVID: Assessing the impact of the COVID-19 pandemic on the indian oncology marketCancer patients in particular experienced impacts to many aspects of their care – two years on we reflect on specific effects seen in the Indian oncology market and how we believe a promising new upturn is taking shape.

In this paper, we combine data from three Ipsos studies conducted in India with our current therapy expertise and market insight, to outline how the COVID-19 pandemic influenced drug-treated cancer patient estimates, oncology drug revenue estimates and patient caseload management.

We also offer a forward-looking perspective on how we believe new healthcare initiatives put in place in this region may alleviate the effects of the pandemic and the future cancer treatment landscape.

Download

The author(s)

More insights about Health

Related news

  • KEYS: Our World in Motion
    E mobility Webinar

    [Webinar] KEYS: Our World in Motion

    At our next KEYS webinar, we’ll be launching the inaugural Ipsos Mobility Report.
  • [Webinar] Real evidence from real experiences: Patient Centric Evidence
    Healthcare Webinar

    [Webinar] Real evidence from real experiences: Patient Centric Evidence

    Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
  • Battle For Attention - KEYS Webinar from Ipsos
    Communications Events replay

    [Webinar] KEYS: Battle For Attention

    In today’s hyper-fragmented landscape, communicating using short-form content and social media platforms is an essential part of our toolkit. But are they better suited to short-term engagement rather than long-term brand building? And what does genuinely innovative and creative advertising look like these days?